[Alveolar Epithelial Cell Injury As an Etiopathogenic Factor in Pulmonary Fibrosis]

Overview

Journal Arch Bronconeumol

Specialty Pulmonary Medicine

Date 2012 Nov 3

PMID 23116901

Citations 3

Authors

Anna Serrano-Mollar

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by a progressive accumulation of extracellular matrix and an imbalance between profibrotic and antifibrotic mediators. In the last few years, understanding of the mechanisms of the biology of IPF has increased. One of the most significant discoveries is the finding that alveolar epithelial cell injury plays an important role in the pathogenesis of this disease. In this review, we describe some of the mechanisms involved in alveolar cell injury and their contribution to the development of IPF.

Citing Articles

Oxymatrine inhibits TGF‑β1‑mediated mitochondrial apoptotic signaling in alveolar epithelial cells via activation of PI3K/AKT signaling.

Feng T, Duan R, Zheng P, Qiu J, Li Q, Li W Exp Ther Med. 2023; 25(5):198.

PMID: 37090069 PMC: 10119625. DOI: 10.3892/etm.2023.11897.

The gut-lung axis: Gut microbiota changes associated with pulmonary fibrosis in mouse models induced by bleomycin.

Quan Y, Yin Z, Chen S, Lang J, Han L, Yi J Front Pharmacol. 2022; 13:985223.

PMID: 36249808 PMC: 9561135. DOI: 10.3389/fphar.2022.985223.

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier.

Camelo A, Dunmore R, Sleeman M, Clarke D Front Pharmacol. 2014; 4:173.

PMID: 24454287 PMC: 3887273. DOI: 10.3389/fphar.2013.00173.

References

Barr R, Bourbeau J, Camargo C, Ram F . Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax. 2006; 61(10):854-62. PMC: 2104759. DOI: 10.1136/thx.2006.063271. View

Boushey H, Enright P, Samet J . Spirometry for chronic obstructive pulmonary disease case finding in primary care?. Am J Respir Crit Care Med. 2005; 172(12):1481-2. DOI: 10.1164/rccm.2509009. View

Cranston J, Crockett A, Moss J, Alpers J . Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; (4):CD001744. PMC: 6464709. DOI: 10.1002/14651858.CD001744.pub2. View

Miravitlles M . Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med. 2011; 105(8):1118-28. DOI: 10.1016/j.rmed.2011.02.003. View

Boyd G, Morice A, Pounsford J, Siebert M, Peslis N, Crawford C . An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1997; 10(4):815-21. View

Peters S, Kunselman S, Icitovic N, Moore W, Pascual R, Ameredes B . Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010; 363(18):1715-26. PMC: 3011177. DOI: 10.1056/NEJMoa1008770. View

Yin P, Jiang C, Cheng K, Lam T, Lam K, Miller M . Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet. 2007; 370(9589):751-7. DOI: 10.1016/S0140-6736(07)61378-6. View

Watz H, Waschki B, Meyer T, Magnussen H . Physical activity in patients with COPD. Eur Respir J. 2008; 33(2):262-72. DOI: 10.1183/09031936.00024608. View

Berger R, DeCamp M, Criner G, Celli B . Lung volume reduction therapies for advanced emphysema: an update. Chest. 2010; 138(2):407-17. DOI: 10.1378/chest.09-1822. View

10.

Otero Candelera R, Grau Segura E, Jimenez Castro D, Uresandi Romero F, Lopez Villalobos J, Calderon Sandubete E . [Prophylaxis of venous thromboembolism]. Arch Bronconeumol. 2008; 44(3):160-9. DOI: 10.1016/s1579-2129(08)60031-2. View

11.

Vidal R, Blanco I, Casas F, Jardi R, Miravitlles M . [Guidelines for the diagnosis and management of alpha-1 antitrypsin deficiency]. Arch Bronconeumol. 2006; 42(12):645-59. DOI: 10.1016/s1579-2129(07)60007-x. View

12.

. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980; 93(3):391-8. DOI: 10.7326/0003-4819-93-3-391. View

13.

Monteagudo M, Rodriguez-Blanco T, Parcet J, Penalver N, Rubio C, Ferrer M . Variability in the performing of spirometry and its consequences in the treatment of COPD in primary care. Arch Bronconeumol. 2011; 47(5):226-33. DOI: 10.1016/j.arbres.2010.10.009. View

14.

Mannino D, Buist A . Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370(9589):765-73. DOI: 10.1016/S0140-6736(07)61380-4. View

15.

Boulet L, Lemiere C, Archambault F, Carrier G, Descary M, Deschesnes F . Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. Chest. 2006; 129(3):661-8. DOI: 10.1378/chest.129.3.661. View

16.

Hurst J, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363(12):1128-38. DOI: 10.1056/NEJMoa0909883. View

17.

DeWalt D, Berkman N, Sheridan S, Lohr K, Pignone M . Literacy and health outcomes: a systematic review of the literature. J Gen Intern Med. 2004; 19(12):1228-39. PMC: 1492599. DOI: 10.1111/j.1525-1497.2004.40153.x. View

18.

Bradley J, ONeill B . Short-term ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; (4):CD004356. PMC: 9039969. DOI: 10.1002/14651858.CD004356.pub3. View

19.

Singh J, Palda V, Stanbrook M, Chapman K . Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch Intern Med. 2002; 162(22):2527-36. DOI: 10.1001/archinte.162.22.2527. View

20.

Sapey E, Stockley R . COPD exacerbations . 2: aetiology. Thorax. 2006; 61(3):250-8. PMC: 2080749. DOI: 10.1136/thx.2005.041822. View